Drug · PCSK9 / LDL-C · PCSK9 / LDL-C · Verified drug
Evolocumab (Repatha) structure · mechanism
Anti-PCSK9 monoclonal antibody — Q2W/QM SC injection class peer to oral enlicitide.
Evolocumab (Repatha) 2D structure
- Role
- Drug
- Mechanism class
- PCSK9 / LDL-C
- Parent scaffold
- PCSK9-binding macrocyclic peptide pharmacophore
- Indication
- Hypercholesterolemia / ASCVD · FDA/EMA
- Structure source
- Catalog seed (external identifier on file)
- ChEMBL ID
- CHEMBL2107838
- FDA / EMA
- FDA/EMA
- ClinicalTrials.gov
- evolocumab PCSK9
- Regulatory status
- Approved · FDA/EMA · ClinicalTrials.gov · ClinicalTrials.gov
Hand-written analysis
Mechanism
에볼로쿠맙은 순환 PCSK9를 중화하는 완전 인간 IgG2 단클론항체입니다. PCSK9가 LDL 수용체를 분해하지 못하면 간 표면 수용체가 늘어 LDL-C가 떨어집니다. 주사 제형입니다.
Medicinal chemistry
소분자가 아니라 mAb입니다. 인클리시란(siRNA)·경구 매크로사이클과 모달리티가 갈립니다.
Indication · context
가족성 고콜레스테롤·죽상경화 고위험에서 스타틴에 더합니다. PCSK9 허브의 항체 축입니다.
SMILES
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)OTags
Related compounds
Comparisons · briefs
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.